n=56; $\chi^2 P=0.41$) of patients initiated on anti-TNF received at least one course of antibiotics.

Conclusions During the post-initiation maintenance period of first-line biologic therapy in patients with UC, patients initiated on VDZ were significantly less likely to be prescribed corticosteroids than matched patients initiated on anti-TNF agents. Numerically less patients on VDZ received antibiotics, however this did not reach significance.

### Abstracts

**P112 IMPACT OF THERAPEUTIC DRUG MONITORING ON OUTCOMES FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE**

Arif Hussenbux*, Tanya Chopra, Rebecca Steams, Rahul Ravindran, Nishant Patodi, Aminda De Silva. Royal Berkshire Hospital, Reading, UK

10.1136/gutjnl-2020-bsgcampus.187

**Introduction** Anti-tumour necrosis factor α biological drugs have proven efficacy in the management of inflammatory bowel disease (IBD). Among infliximab and adalimumab treated cohorts, primary non response occurs in up to 30% and secondary non response occurs in up to 46% of patients. Therapeutic drug monitoring (TDM) is a useful tool for optimising drug dosing and modification. The aim of this study is to assess the appropriateness and effectiveness of TDM in IBD patients in a large UK district general hospital.

**Methods** This was a retrospective study. Patients with Crohn’s disease (CD) and Ulcerative Colitis (UC) on infliximab and adalimumab were identified from 2017 – 2019. Clinician’s response to TDM results were monitored. CRP and faecal calprotectin up to 3 months before and after TDM with appropriate management were recorded. Hospital admission and surgery rates were compared between the TDM and non-TDM cohorts. Wilcoxon signed rank and Mann-Whitney test were applied to determine statistical significance.

**Results** 364 patients were included (281 CD, 73 UC, 10 IBD-unclassified; 204 on infliximab, 160 on adalimumab). 209 (57.4%) patients were tested for TDM at least once during unclassified; 204 on infliximab, 160 on adalimumab). 209 (57.4%) patients were tested for TDM at least once during unclassified; 204 on infliximab, 160 on adalimumab). 209 (57.4%) patients were tested for TDM at least once during unclassified; 204 on infliximab, 160 on adalimumab). 209 (57.4%) patients were tested for TDM at least once during unclassified; 204 on infliximab, 160 on adalimumab). 209 (57.4%) patients were tested for TDM at least once during unclassified; 204 on infliximab, 160 on adalimumab).

**Conclusion** CRP and faecal calprotectin significantly reduced after TDM and appropriate management. Hospital admissions and surgery were significantly less in the TDM group. There are limitations due to retrospective design and confounding factors; we acknowledge the TDM group tended to have closer monitoring, which may have led to better outcomes. This study demonstrates TDM as a powerful tool in personal care for inflammatory bowel disease.

---

**P113 THE USE OF VEDOLIZUMAB IN A SECONDARY CARE DGH SETTING; REAL WORLD EXPERIENCE AND OUTCOMES**

1Mohit Inani*, 2Jamal Ahmed, 3Heleen Steed, 3Ashit Shah, 3Kravindhan Murugananthan, 3Hari Padmanabhan, 3Matthew Brookes. 1Wye Valley Nhs Trust, Hereford, UK; 2Royal Gwent Hospital, Newport, UK; 3New Cross Hospital, Wolverhampton, UK

10.1136/gutjnl-2020-bsgcampus.188

**Introduction** To evaluate the clinical and biochemical outcomes of patients with inflammatory bowel disease to Vedolizumab at a District General Hospital

**Methodology** Retrospective cohort study assessing 55 patients administered Vedolizumab between 2015 and 2019. Demographics and clinical information were recorded. Response was determined using Harvey Bradshaw (HB) and partial Mayo score (pMS). Baseline indices and serum CRP were recorded at (i) prior to commencement, (ii) 6 months, and (iii) 12 months. A clinical response was determined by a decrease in pMS and HB of at least 3 points for UC and CD respectively or to a score below 5.

**Results** A total of 55 patients (33 CD, 22 UC) were found on our electronic records. A total of 44 (18 UC, 26 CD) were included with 11 patients excluded as they had started within 6 months of study commencement.

Mean age for UC was 45.2 years and CD was 42.8 years, 15/18 (83.3%) UC patients and 20/26 (76.9%) CD patients had prior anti TNF exposure. 56% (5/9) of all those TNF naïve were found to have a response at 6 months.

**UC group**

Mean CRP reduction at 6 and 12 months was -7.1 and -6.3 respectively. Mean pMS prior to treatment 5.8 and at 6 months was 4.8. At 6 months, 66% (n=18) were responders, 61% (11/18) were partial responders and 33% (n=6/18) were non responders. 67% (n=12/18) completed 12 months treatment when 8% (n=1/12) were responders, 58% (n=7/12) partial responders and 33% (n=4/12) were non responders.

**CD group**

Mean CRP reduction at 6 and 12 months were -7.7 and -7.2 respectively. Mean HB prior to treatment 7.7 and at 6 months was 5.7. At 6 months, 19% (n=5/26) were in clinical remission, 15% (n=4/26) were responders, 46% (n=12/26) were partial responders and 19% (n=5/26) non responders. 65% (n=17/26) completed 12 months treatment, of those 23.5% (n=4/17) were in clinical remission, 17.6% (n=3/17) were responders, 41% (n=7/17) were partial responders and 17.6% (n=3/17) were non responders.

Reasons for stopping treatment in all patients: treatment was stopped prior to completion of 12 months in 15/44 (34%) patients. This included need for surgery 4.5% (2/44), abnormal liver function tests 9% (n=4/44), intolerance 18% (8/44), and pregnancy 2.2% (1/44).

**Conclusion** Our results reflect similar safety and efficacy of Vedolizumab to published data. Vedolizumab was generally well tolerated with no serious adverse effects.